Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed Brendan P. Rae, Ph.D., J.D., to the position of Chief Business Officer, effective November 1, 2011. In this role, Dr. Rae will lead the Company's licensing and business development efforts with a focus on establishing corporate partnerships and strategic alliances worldwide.

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Pasadena, CA | Posted on November 3rd, 2011

In addition to practicing patent law, Dr. Rae has worked as a licensing and business development professional in the pharmaceutical and biotechnology industries over the last 15 years. In this capacity, he has successfully sourced new products, led due diligence and commercial evaluation teams, and negotiated and executed agreements in the US, Europe and Far East. Most recently, Dr. Rae was the Chief Business Officer of Vivaldi Biosciences Inc., an influenza vaccine development company headquartered in New York City. Prior to that, he served, from 2005 to 2010, as Senior Vice President, Licensing and Business Development at VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of therapies for the treatment of cardiovascular disease. Dr. Rae's pharmaceutical licensing experience was gained at Hoffman-La Roche Ltd., where he directed the company's in-licensing and out-licensing activities from 1996 to 2003, and at Purdue Pharma L.P. Dr. Rae practiced patent law at the firm of Amster, Rothstein & Ebenstein, LLP.

"Establishing this role is a key element in our strategy to build long-term value for our shareholders through a combination of in-house R&D and strategic partnership agreements," said Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead. "Brendan's in-depth knowledge of and expertise in business development for biotechnology and pharmaceuticals companies will serve the Company well as we work to advance and partner our drug candidates. On behalf of our management and Board, I welcome Brendan to our team."

Dr. Rae added, "Arrowhead has established a comprehensive and advanced portfolio of leading RNAi technology and IP, which firmly positions the Company as a likely candidate for large industry partnerships. I am excited to join the Arrowhead team and look forward to playing an active role in helping the Company build on its success."

Dr. Rae obtained his Bachelor of Science degree in Microbiology from Glasgow University, and was awarded a Ph.D. by the Institute of Virology in Glasgow, Scotland. He was a Postdoctoral Fellow at the Roche Institute of Molecular Biology. Dr. Rae has served as an Adjunct Assistant Professor, Department of Microbiology and Immunology, at the New York Medical College since 1989, and a Visiting Professor in the School of Host Infection and Immunity at Liverpool University since 2008. Dr. Rae earned his Juris Doctor degree from Seton Hall Law School in Newark, New Jersey.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to .

NASDAQ Notice

As an inducement to his entering into employment with the Company, Dr. Rae was awarded an "inducement" option under the NASDAQ Marketplace Rules. The option entitles Dr. Rae to purchase, outside of the Company's stockholder approved equity incentive plans, an aggregate of up to 175,000 shares of the Company's common stock at an exercise price per share equal to the last reported closing price of the Company's common stock on the date of grant. The option vests and becomes exercisable over a period of four years from the date of grant.

Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Investor Relations Contact:
Brandi Floberg or Kathy Price
The Piacente Group, Inc.
212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists Capture Ultrafast Snapshots of Light-Driven Superconductivity: X-rays reveal how rapidly vanishing 'charge stripes' may be behind laser-induced high-temperature superconductivity April 16th, 2014

'Life Redesigned: The Emergence of Synthetic Biology' Lecture at Brookhaven Lab on Wednesday, April 30: Biomedical Engineer James Collins to Speak for BSA Distinguished Lecture Series April 16th, 2014

ECHA Planning Workshop on Regulatory Challenges in the Risk Assessment of Nanomaterials April 16th, 2014

Lumerical files a provisional patent that extends the standard eigenmode expansion propagation technique to better address waveguide component design. Lumericalís EME propagation tool will address a wide set of waveguide applications in silicon photonics and integrated optics April 16th, 2014

Nanomedicine

UT Arlington physicist creates new nanoparticle for cancer therapy April 16th, 2014

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

PAM-XIAMEN Offers UV LED wafer April 15th, 2014

Nanocrystalline cellulose modified into an efficient viral inhibitor April 15th, 2014

Announcements

UT Arlington physicist creates new nanoparticle for cancer therapy April 16th, 2014

Relieving electric vehicle range anxiety with improved batteries: Lithium-sulfur batteries last longer with nanomaterial-packed cathode April 16th, 2014

Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMCís Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE